GIANT: Evaluation of the genetic profile of CYP2C19 in patients undergoing primary angioplasty

The aim of this study was to evaluate the clinical impact resistance thienopyridines through genetic analysis of CYP2C19 receptor. The primary endpoint was  a combination of mortality, myocardial infarction, stent thrombosis in the resistance group (few responders) versus non-resistant (responders) to the thienopyridines. 1445 patients were included of which 22% were considered few responders. There was no difference in the primary endpoint between responders and nonresponders (3% for both groups, P = .83).

Descargar (PDF, Unknown)

Bernard R. Chevalier
2013-10-31

Original title: GIANT: A Prospective Registry Study of CYP2C19 Genetic Profiling for Thienopyridine Management After Primary PCI in Acute Myocardial Infarction

*

Top